Editorial Board Member - JAHI
Dr. Xinyong Liu is currently a distinguished principal professor, a designated Ph.D. advisor, Director of the Institute of Medicinal Chemistry, Vice Dean of the School of Pharmaceutical Sciences, Shandong University. He obtained his Ph.D. from Shandong University in 2004. In his medicinal chemistry research fields, he has published more than 300 paper and 6 monographs. In addition, 26 patents have been granted presently.
Dr. Xinyong Liu research work is partly engaged in the rational drug design, synthesis and antiviral evaluation of a variety of molecules that interact with specific enzymes and receptors in viral life cycle (HIV, HBV, HCV, Flu). (1) in anti-HIV drug research, He is focusing on the design and synthesis of novel non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs), and the novel multiple ligands (inhibitors) simultaneously targeting at HIV-1 RT and integrase. (2) in anti-HBV drug research, he is focusing on design and synthesis of some novel non-nucleoside (small molecules) inhibitors. (3) in anti-influenza drug research, he is conducting the neuramidinase inhibitors and RNA polymerase inhibitors. His second ongoing program is design, synthesis and cardiovascular studies of novel factor Xa inhibitors, and synthesis of some natural products from Chinese Traditional Medicine active in cardio/vascular diseases.
Other Editorial Board Members - JAHI
Ethiopian Universities' Partnership Forum
Department of Microbiology and Infectious Diseases
University of Buenos Aires
Institute for Molecular Virology
Saint Louis University School of Medicine
Department of Psychiatry
University of Pennsylvania and Treatment Research Institute
School of pharmaceutical sciences
Department of Bioinformatics
Kwara State Specialist Hospital